Objective: Sex hormone-binding globulin (SHBG) binds and transports testosterone and estradiol in plasma. The possibility that SHBG is a mixture of transporting proteins has been postulated. We analyzed 36 in parallel the effects of obesity status on the levels and binding capacity of circulating SHBG and their relationship with testosterone and estradiol. 38
, as well as its more than probable implication in metabolic 60 syndrome (MS) 8 .
The function of SHBG is far from being fully understood. In fact, although it binds the hormone 62 ligands in a high-affinity specific way, SHBG levels in plasma are low in comparison with albumin and other plasma proteins. The latter bind non-specifically these same hormones with high capacity and low 64 affinity. The equilibrium of free hormone levels, thus, is not solely dependent on SHBG binding ability or levels, but also on its interaction with tissues and their complex and variably modulated compartmentation 66 9 . The absence of SHBG in rodents, in contrast with CBG, present in them and in humans, may hint at additional functions for this serpin, but the presence of a specific testosterone-binding protein in rodent 68 testicles 10 , with a marked structural and gene parallelism with SHBG 11, 12 suggests that at least for this organ, a specific protein binding testosterone is required. 70
The high-affinity binding of sex hormones to SHBG competes with cell receptors, altering its direct availability, which prompts the question whether SHBG main role is to transport the hormones, or 72 retain them to modulate their binding to cell membranes, including the specific binding of SHBG itself 13 . This sequestering role has been postulated for tissues, where membrane-related hormone-binding 74 globulins may act barrier-like to limit or control the access of active hormones to cells, as is the case for CBG 14 . However, hormone-binding globulins are required as vector for transfer of hormones to cell 76 ligands 15 , to elicit effects on gene expression and the activation of other cell functions 16, 17 .
SHBG is a glycoprotein 18 , which appears in plasma as a dimer, containing two subunits, each 78 one having a site able to bind testosterone, dihydrotestosterone or estradiol 19 . The affinity for testosterone has been found to be higher than for estradiol 20 in line with the function of the precursor 80 testosterone-binding protein of rodents compared with that of plasma and testicles in rabbits 21 . In human plasma, SHBG has been found in several forms of variable molecular weight, distributed in markedly 82 different proportions 22, 23 ; however, they shared the peptide size and immuno-reacting properties, albeit only partially 22, 24 . The difference in size has been largely attributed to the varying proportion of 84 oligosaccharide chains 23, 25 . SHBG hormone-binding affinity can be changed by molecular modulation of the serpin structure, such as localized proteolysis 26 , proteolytic cleavage resulting in increased free 86 hormone levels because of loss of affinity of the protein to its ligand 2 . Other possible modifications of SHBG structure / binding are the formation of O-or N-glycans 27, 28 . An important factor of variability / 88 regulation is the complex control 29, 30 of the expression of the single SHBG gene described 12 , able to generate different products 12 . In addition, a number of genetic variants, showing different hormone-90 binding affinities, has been described 31, 32 . Plasma concentrations of free testosterone and estradiol are related to the levels of SHBG 33 . Sex 92 affects markedly the levels 34, 35 and function of SHBG, essentially altering the levels of testosterone . SHBG has been associated to the risk of MS in men 38, 42 , independently of testosterone levels 43 , whereas the relation of this syndrome with total or free testosterone is -at 98 most-weak 44, 45 . . In the present study 102
we studied whether SHBG function is modified by obesity status. The key question was to determine whether the changes that SHBG experiences with obesity are a direct consequence of the existence of 104 different molecular species of this protein.
106

SUBJECTS AND METHODS
Study population 108
A sample of 62 subjects (32 of them women) of Caucasian origin, aged between 18 and 50 y (i.e. . Inclusion criteria, in addition to the BMI ranges described above, were the absence of any systemic disease, and 116 the absence of any infections in the previous month. None of the subjects was taking medication (including glucocorticoids or estrogens) or showed evidence of metabolic disease other than obesity. All 118 subjects reported that their body weight had been stable for at least 3 months before the study. Liver disease and thyroid dysfunction were specifically excluded by biochemical workup. All women had regular 120 menstrual cycles and were studied on days 3-8 of the cycle. All participants were in apparently good health, and free of cardiovascular pathologies, clinically defined diabetes or hypertension. 122
The protocol was approved by the Hospital Ethics Committee, and informed consent was obtained from each subject. 124
Baseline studies included a standardized questionnaire, physical examination and common laboratory tests. Height and weight were measured with the participant in light clothing and barefoot. BMI 126 was calculated, and blood pressure was measured in the supine position, using a sphygmomanometer of appropriate cuff size; the first and fifth phases were recorded. 128 F o r R e v i e w O n l y 5 at 100 pM and 620 pM, respectively. Blood glycosylated hemoglobin (HbA1c) proportions were analyzed 138 by high pressure liquid chromatography (Merck Diagnostics, Darmstadt, Germany), with coefficients of variation below 4%. The range for HbA1c in glucose-tolerant subjects was 3.8 -5.4%. Total serum 140 cholesterol was measured through the reaction of cholesterol esterase/oxidase/ peroxidase, using a BM/Hitachi 747 analyzer (Hitachi, Tokyo, Japan). HDL cholesterol was quantified after precipitation with 142 polyethylene glycol at room temperature. Total serum triacylglycerols were measured through lipolysis and the analysis of glycerol evolved with glycerol-phosphate-oxidase/ peroxidase. Whole blood 144 hemoglobin levels (containing EDTA) were determined by a routine laboratory method (Coulter Electronics, Hialeah, FL USA). 146
Solid-phase enzyme-linked immunosorbent assays (ELISA) based on the sandwich principle were used for the quantitative determination of plasma estradiol (kit EIA-2693) and testosterone (kit EIA-148 1559, both from DRG International; Marburg, Germany). Plasma cortisol was determined by microparticle enzyme immunoassay (IMX system, Abbott Laboratories, North Chicago, IL USA), with intra and 150 interassay coefficients of variation less than 8% 51 .
152
Western blot of SHBG µL of plasma were used. Proteins were transferred to PVDFImmobilon (Millipore, Billerica, MA USA) membranes, which were visualized with Ponceau red. The membranes were blocked with TBST and 50 160 gL -1 powdered skimmed milk; then they were incubated at 4 ºC overnight with the primary antibody diluted 1/2000. The membranes were, then, washed four times and then exposed (for 1 h at room 162 temperature), diluted 1/3000, to the secondary antibody. After four washings, chemiluminiscence was analyzed using ECL (Millipore) for 5 min. Then, densitometric measurements were done using the Total-164
Lab program (Nonlinear USA, Durham, NC USA). This Western blot is an adaptation of that previously developed by our group for the measurement of rat plasma CBG 52 . 166
Hormone-binding assays 168
The basic procedure for hormone-binding assays was the same described by us previously for Perkin-Elmer, Boston MA USA; specific activity 2.8 GBqmmol -1 ) or testosterone (NET370: (1,2,6,7 3 H)-testosterone, Perkin-Elmer, specific activity 2.6 GBqmmol -1 ). Hormones' final concentration was 30 nM, 174 with a specific radioactivity of 12 kBqnmol -1 ). Non-specific binding was estimated under the same conditions, but now adding 0.025 mL of non-labelled hormone in PBS-gelatin (final concentration 15 µM). 176
In both cases, the tubes were incubated under gentle shaking for 20 min at 37 ºC followed by 2 h at 4 ºC. and kept 10 min in ice. Finally, the tubes were centrifuged 10 min at 4 ºC and 2,000xg. Aliquots of the supernatants were used to measure the radioactivity bound to protein through liquid scintillation counting. 180
Statistical methods 182
Statistical comparisons were done using two-way ANOVA analyses (sex, obesity), with the Statgraphics Centurion XVI program package (Statpoint Technologies, Warrengton VA USA). 184
Correlations were determined using the Prism 5 package (Graph-Pad Software Inc, La Jolla, CA USA).
Before statistical analysis, normal distribution and homogeneity of the variables were tested. Levels of 186 statistical significance were set at P <0.050. Table 1 shows the basic plasma anthropometric and metabolic values of the six experimental 190 groups. As expected, increased weight was concomitant with higher triacylglycerol levels in men and women, as well as with increased glycaemia, insulin and HOMA-IR. 192 Table 2 presents the levels of plasma hormones and ratios between these levels. Estradiol concentrations showed no significant differences between women (in the follicular phase) and men. 194
188
RESULTS
Morbid obesity was associated with increased estradiol levels, especially in men. As expected, testosterone showed marked sex-related differences, increasing with the severity of obesity in women 196 and decreasing in men. No significant differences were observed regarding basal cortisol
The ratio of testosterone to estradiol concentrations showed significant differences according to 198 sex and obesity. Cortisol/ testosterone ratios were significantly different in obese women, but not in obese men. In contrast, the cortisol/ estradiol ratio was significantly different in obese men. The estradiol/ insulin 200 ratios were similar according to sex and obesity status; however, the testosterone/ insulin ratios were clearly different for sex and BMI, being the effects of obesity a consequence of the 6-fold difference 202 between morbidly obese men and controls.
Plasma SHBG binding capacity for estradiol and testosterone is depicted in Figure 1 . Estradiol 204 binding showed no significant effect of sex, but obesity severity resulted in significant differences, solely attributable to males, since the morbid obese had much higher and significantly different binding values 206 than those obese or with normal weight. The pattern for testosterone binding was quite different, with significant effects of both sex and obesity, the latter attributable, again to the group of men, with morbidly 208 obese subjects showing the lowest testosterone binding values. These differences were magnified in the estradiol vs. testosterone binding ratio. Both sex and obesity showed significant differences, with rather 210 uniform ratios for all groups except for the morbid obese men, with ratios several-fold higher than in all other groups. 212 Figure 2 shows the levels of testosterone and estradiol as a proportion of SHBG binding capacity.
The only significant differences observed were for sex in the case of testosterone, since in men the levels 214 accounted for 60-80% of maximal binding capacity of SHBG against 5-20% for women. These data contrast with the rather uniform 1-3 % values for estradiol levels vs. binding. 216 ability to bind was a uniform correlate of the amount of SHBG available, but in morbid obese men the ability to bind estradiol was much higher than that corresponding to the protein detected. In the case of 228 testosterone, however, no significant differences for sex or obesity were found, with closely similar ratios of binding/ SHBG protein ratios for all groups. That is, under the testing conditions, the affinity and capacity to bind a given hormone (testosterone or estradiol) should remain unchanged. However, the binding / Western blot ratios, experimentally obtained, 242 clearly were not. This result proves that in one of the groups of individuals (e.g. all the morbidly obese men), the SHBG molecule was structurally different. 244
The existence of varying molecular weight SHBG proteins 28 , and the influence of the size of the monomers on binding has been already described 53 . However, the marked change in SHBG ability to bind estradiol in the group of morbidly obese men here described is outstanding. 250
The binding/ Western ratio for testosterone, was similar in all groups, as expected, including the morbidly obese men who also had the lowest levels of immunoreactive SHBG. The hormones' binding 252 ratios did not show the expected uniform pattern, strongly deviated in morbid obesity instead; however this deep change affected only men. Last, but not least, the relationship between the binding capacity of 254 SHBG and the circulating hormone levels showed large differences for testosterone and estradiol ( Figure   2 ), in addition to the marked difference due to sex, largely a correlate of the higher circulating 256 testosterone levels of men. In any case, the percentage of hormone levels vs. binding in control women was in the range of 1.5 % whereas that of testosterone was fivefold higher. These values were not within 258 the expected range of work for SHBG to exert its transporting function under normal conditions; i.e. when when we consider that SHBG is also a carrier for hormones that bind to specific membrane sites to transfer their charge 63 . In addition, most studies on SHBG function were centered on testosterone 64, 65 . 282
As a comparison, CBG is devoted to the control of cortisol (or corticosterone in rodents), but also binds progesterone and a number of other ligands 66 ; nnevertheless, no role of CBG in transport or control of 284 progesterone has been definitively proven. There is thus a clear parallelism between both serpins.
The apparent increase of estradiol-binding "capacity" in morbidly obese men should be explained 286 in terms of increased SHBG protein levels, but they were not. Furthermore, testosterone levels were unaffected, and the ratios for testosterone binding / Western blot were uniform for all men (and women) 288 groups, a situation completely different to that of estradiol. A possible explanation of this inconsistency must lie on the existence of more than one type of SHBG protein, with at least one specifically binding 290 estradiol, and the other to testosterone. Thus justifying the data observed in this study, despite testosterone alone responding as expected. This interpretation is coincident with previous reports that 292 found different molecular species of SHBG binding either androgen or estradiol, but not both (in cirrhotic patients) 54 , as well as the importance and common occurrence of SHBG alleles 22 . 294
The extreme change in estradiol binding of morbidly obese men in comparison with the other groups could not be explained by the measured (Western) SHBG protein. But testosterone complies 296 under the same conditions. Since estradiol levels were much lower, a plausible Estradiol-Binding Globulin should be present in the morbidly obese men plasma in lower levels than the "current" or "testosterone-298 prone" SHBG. This situation mimics that described for cirrhosis 54 . The "estradiol-prone" SHBG, An additional clue to the importance of the antagonistic gender-related function of cortisol and testosterone 37 can be directly derived from the analysis of their concentration ratios, markedly decreased 318 with obesity in women and less affected in men. These differences are difficult to explain with the assumption of a unique SHBG regulating both testosterone and estradiol, since the cortisol / estradiol 320 concentration ratios were affected by obesity but not by sex. A similar picture can be drawn from the ratios of both sex hormones versus insulin: no effects were observed for estradiol, but men (albeit not 322 women) showed marked effects of obesity, depending on its severity. These data hint at a much more significant (and gender-related) implication of testosterone in obesity 70 . This is in agreement with the sex-324 related incidence of the development of MS with age . Since the fall in testosterone levels, at least in men, tend to be related to age 69 , and this occurs in parallel to a fall in SHBG levels 65 , 332
we can assume that the results obtained in the present study should be extended to a larger population, with a wide age range. The important amount of data available on the dynamics of testosterone action 334 and protein deposition 77 _ENREF_37 in conjunction with the main anabolic hormone, insulin, countered by corticosteroids 37 show that testosterone is a critical factor in the aging process 78 . The discriminating 336 role of the postulated dual SHBGs may help understand better the gender-related process of aging by establishing a clear mechanism of regulation of the plasma kinetics and transport of testosterone, but will 338 also allow a deeper study of estrogens without interference.
In conclusion, our data point to SHBG as a globulin mainly centered in the control of testosterone 340 levels, with estradiol regulation taking a markedly second place; or, simply, estradiol being controlled by a different SHBG variant. These data confirm the existence of different SHBG molecular species to 342 discriminately bind estradiol and testosterone, previously reported in cirrhotic subjects 54 . The sex-related differences in the relationships of binding versus levels of hormones and SHBG could not be explained by 344 assuming that a single dimeric protein may experience the dramatic changes in affinity for testosterone and estradiol (differently for both, in fact) observed in women and men, and the marked differential effects 346 of obesity on the ability of the same protein to bind testosterone and estradiol (Box 1).
Thus, we postulate that SHBG protein must be present in at least two different molecular species, 348 or isoforms, to explain its differential function for both hormones, specially affected by sex and obesity.
These conclusions suggest a much needed establishment of analytical procedures to identify these 350 physiologically distinct forms of SHBG, since the sole use of antibody-based measurements could not discriminate between them. 352
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Current accepted knowledge:
A unique SHBG binds, transports and regulates the levels and availability of T and E2 Already known data that so not support the "single SHBG" current theory • M and W show different (and varying) levels of T and E2 with similar SHBG protein concentrations • Widely different T and E2 levels in plasma apparently do not compete or interfere on SHBG function despite using a single binding site for which they compete as ligands • Different SHBG forms have been found in humans with structural and binding affinity differences for T and E2) • Many animals do not have SHBG, but most possess non-circulating T-binding proteins; i.e. T may be regulated independently of E2. In any case T and E2 levels are regulated in plasma despite the eventual absence of SHBG Additional proof, presented here, against the "single SHBG" current theory
• Circulating E2 (lower than T) at most may cover 3% of the potential binding sites of concurrent plasma SHBG, which is not compatible with T occupying 65-90 % of the sites. These data anr not compatible with a regulation role of SHBG for E2 • Obesity affects T (but not E2) binding. This is incompatible with both hormones binding (competing) for the same SHBG binding site if the protein remains unchanged • The ratio of hormone binding vs. protein level (Western blot) should be constant unless the protein affinity is changed (by changing the protein itself). The ratio for T is unaltered by sex and obesity, but that for E2 is affected by both The conclusions are far reaching:
• Cannot be explained by the single type of SHBG, which brings us to assume that, at least there are two SHBGs, one regulating T and the other for E2 • Most of the methods used for the measurement of SHBG rely on their immunoreactivity, but they may detect/ measure a T-or E2-prone SHBG molecular species of a mixture of both in different proportions • Consequently, there are no reliable methods for SHBG measurement available, in the sense that SHBG levels could not be related to a specific protein carrying out a specific function. This, largely invalidates many studies on SHBG function • Specific discriminative methods for the SHBGs may help clarify the intuited role of estrogens and androgens on metabolic syndrome-related pathologic states.
